Aurobindo Pharma Limited has inaugurated TheraNym Biologics, a dedicated biologics contract manufacturing organization (CMO) facility in Telangana, marking a significant expansion of the company’s presence in the fast-growing global biologics sector. Located at Borapatla near Hyderabad, the facility has been established to provide end-to-end biologics manufacturing services for global pharmaceutical companies. The inauguration ceremony was attended by Telangana Minister for IT, Industries & Commerce and Legislative Affairs Shri D. Sridhar Babu and Minister for Science and Technology Shri Damodar Raja Narasimha. Prior to the event, Aurobindo Pharma’s leadership team and representatives from MSD met Telangana Chief Minister Shri Anumula Revanth Reddy to discuss the project and acknowledge the state government’s support in facilitating the investment.
TheraNym has been developed with advanced manufacturing capabilities, including 15 KL bioreactors, downstream processing systems, aseptic fill-finish operations, and modern quality control laboratories. Designed in line with international regulatory expectations, the facility is positioned to support both domestic and export markets, subject to regulatory approvals and customer requirements.
The facility will serve as an important manufacturing partner for MSD, which has been identified as TheraNym’s anchor customer. The collaboration is expected to strengthen global supply chains for biologic medicines and enhance manufacturing capacity to meet growing demand across international markets.
Dr Satakarni Makkapati, CEO Biologics and Director at Aurobindo Pharma, said the facility represents a major step in advancing India’s capabilities in biologics manufacturing. He noted that TheraNym has been designed to meet the quality, compliance, and operational requirements of leading global pharmaceutical companies while expanding access to biologic therapies worldwide. MSD Executive Vice President and President of Manufacturing Division Dr. Dave Maraldo said the partnership reflects a shared commitment to ensuring reliable and compliant production of biologic medicines for patients across global markets.
Aurobindo Pharma Vice Chairman and Managing Director Nithyananda Reddy highlighted the role played by the Telangana Government in supporting the project through infrastructure development, policy initiatives, and industry engagement. He added that TheraNym complements the company’s biologics ambitions, building on its biosimilars platform and expanding its footprint in complex pharmaceutical manufacturing.
Aurobindo Pharma, headquartered in Hyderabad, is a leading global pharmaceutical company specializing in generic and specialty medicines. It focuses on biosimilars, biologics, and robust manufacturing capabilities, with over 50 billion formulation units and a significant presence in the US market. The company is committed to advancing healthcare through innovation and strategic investments in research and development.
